Medisorb
Medisorb manufacturers proven pharmaceuticals and improves healthcare by making efficient medication affordable.
We successfully brought together the Russian family-run pharmaceutical company Medisorb with CapMan, a Finnish private equity fund worth 2.8 billion euros. CapMan’s minority interest enabled Medisorb to triple its production capacity and grow from being the largest maker of generic drugs in the region of Perm to being the largest in Russia.
Scroll down
The challenge
- We successfully brought together the Russian family-run pharmaceutical company Medisorb with CapMan, a Finnish private equity fund worth € 2.8 billion.
- CapMan´s minority interest enabled Medisorb to triple its production capacity and grow from being the largest maker of generic drugs in the region of Perm to being the largest in Russia.
The solution
To open Medisorb´s doors to the international investment scene, our advisers helped the company restructure its accounting system to meet international standards. This step quickly revealed Medisorb to be an attractive company for investment.
Thanks to its international network and its healthcare expertise, we were able to present Medisorb´s investment case to around 40 international equity funds. With success - because just one month later, Medisorb had received term sheets from several first-rate investment funds. We then helped Medisorb compare the offers objectively and ultimately recommended CapMan as a reliable partner.
Key results
The advisor´s professional support for the external auditors during the due diligence process and its role as an intermediary in the negotiations impressed both Medisorb and CapMan.
And our industry experience was in demand again when the production system was selected: Medisorb decided in favor of a highly powerful system - and tripled its capacity.
Expertise we provided
BEREIT FÜR DIE ZUKUNFT?Lassen Sie uns gemeinsam herausfinden, wie wir Sie unterstützen können!
Was gibt es Neues?Das könnte Sie auch interessieren...
